IncRNA molecule and application thereof in auxiliary diagnosis of colon cancer

• Main Authors: WU HAILI, CUI KAILI, CAO LIJIA, LI HANQING, LI ZHUOYU
• Format: Patent
• Language: Chinese; English
• Published: 22.09.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention relates to the technical field of molecular markers, in particular to an lncRNA molecule and application thereof in auxiliary diagnosis of colon cancer. The invention discloses an lncRNA molecule lncRNA 495810, which can be used as a colon cancer molecular marker or target spot, and can effectively predict the postoperative lifetime of a colon cancer patient, so that a new way is provided for prognosis of colon cancer, a reference basis is provided for clinical doctors to analyze the condition of colon cancer, the lncRNA 495810 is highly expressed in colon cancer, and the result shows that the lncRNA 495810 can be used for detecting the condition of colon cancer. The colon cancer cell proliferation can be promoted, the apoptosis can be inhibited, and the method can be applied to colon cancer auxiliary diagnosis. 本发明涉及分子标记技术领域，具体涉及一种lncRNA分子及其在结肠癌辅助诊断中的应用；本发明公开了lncRNA分子lncRNA495810，其可作为一种结肠癌分子标志物或靶点，可以有效预测结肠癌病人术后生存期，从而为结肠癌预后诊断提供了新途径，为临床医生对于结肠癌病情分析提供了参考依据，lncRNA 495810在结肠癌中高表达，且可以促进结肠癌细胞增殖抑制其凋亡，能够